São Paulo starts applying Pfizer as AstraZeneca’s replacement this Monday, says secretary – Prime Time Zone

4

According to Edson Aparecido, the measure will be valid for people who should take the second dose of Fiocruz’s vaccine between September 1 and 15; immunization should start from 3pm

FABRÍCIO COSTA/FUTURA PRESS/ESTADÃO CONTENT

The city of São Paulo has not yet started the application of the vaccine of Pfizer to replace the second dose of AstraZeneca. The possibility was announced by the state government on Friday, 10, due to the complete shortage of the immunizing agent from Oxford, amid a delay in deliveries by Fiocruz, manufacturing the compound in Brazil. Now, the expectation is that the heterologous application of the compounds will start on the afternoon of this Monday, 13th, explains the municipal secretary of Health, Edson Aparecido. “We received from the state government 165,000 doses of Pfizer and also the instruction for application to people who should take the second dose of AstraZeneca between 1 and 15 September. Let’s discuss [as vacinas] throughout our network and we believe that at around 4 pm the vaccination will be restarted for people who should take AstraZeneca”, he said in an interview with Jornal da Manhã, from Young pan.

Edson Aparecido also spoke about the immunization of adolescents and the application of the third dose to the elderly and immunosuppressed. According to him, more than 80% of young people over 12 years old have already been vaccinated, which, for him, reinforces the success of the campaign in São Paulo. “We have already vaccinated 104% of people with D1, 66% are fully vaccinated. The adhesion of young people was spectacular, 83% vaccinated. Adherence is very high and when we have vaccines available, we can make an escalation”, he pointed out. On the booster vaccine, the secretary said that the capital of São Paulo followed the recommendations of the state and, therefore, applied the vaccines that were available at health posts, which include CoronaVac, Pfizer and AstraZeneca.